- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
Population: Adults (18-64 years)
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- STD/STI clinic
- Monkeypox virus
- Mpox
- Blood sample
- Nasopharyngeal swab
- Skin lesion swab
- Adults (18-64 years)
- People at high risk of STIs
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- People at high risk of STIs
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Blood sample
- Adults (18-64 years)
- People at high risk of STIs
- People living with HIV
- Hospital
- Infectious diseases unit
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- People at high risk of STIs
- Men who have sex with men
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- Monoclonal antibodies
- AZD3152/Sipavibart
- Adults (18-64 years)
- People at high risk of STIs
- Men who have sex with men
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- SARS-CoV-2
- Post COVID-19 condition
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- Hospital
- Outpatient clinic
- Infectious diseases unit
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir